Recently, there have been important advances that could represent novel additions to our existing treatments in primary care practice. This post covers a few frequently asked questions from a recent session that focused on three drugs in particular: zoster vaccine – recombinant adjuvanted (SHINGRIX), erenumab (Aimovig®), and baloxavir marboxil (Xofluza™).
Read more »
